Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence

1 Apr 2025

Abstract excerpt

Amyloid load reduction is an unvalidated surrogate for clinical benefit. Amyloid-targeting antibodies have demonstrated efficacy in both amyloid reduction and slowing cognitive decline due to AD at the mild cognitive impairment (MCI) and mild dementia stages. However, no individual-level mediation analysis has been released to demonstrate that the clinical efficacy of amyloid-targeting antibodies is associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Dementia and Cognitive Impairment Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40243238
DOI: 10.1002/alz.70068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidencePMID 40243238Read ↗

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read ↗

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialSemantic proximity Read ↗

Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab.Semantic proximity Read ↗

Quantification supports amyloid-PET visual assessment of challenging cases: results from the AMYPAD-DPMS studySemantic proximity Read ↗

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brainSemantic proximity Read ↗

Patient attitude towards lecanemab: results from a survey within the European Alzheimer’s disease consortium (EADC), the German memory clinic network (DNG) and Austrian memory centersSemantic proximity Read ↗

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialSemantic proximity Read ↗

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.